Avapag 20 mg (Avatrombopag): Uses, Dosage, Side Effects & Safety
Avapag 20 mg (Avatrombopag): Uses, Dosage, Side Effects & Safety
What Is Avapag 20 mg?
Avapag 20 mg contains avatrombopag, a medicine that works on the thrombopoietin receptor pathway to increase platelet production.
Platelets are blood cells that play an essential role in normal blood clotting. When the platelet count becomes too low, a condition known as thrombocytopenia, the risk of bleeding may increase depending on the severity and underlying cause.
Avatrombopag belongs to a group of medicines known as thrombopoietin receptor agonists. Rather than directly replacing platelets, it stimulates the body's platelet-production pathway in the bone marrow. EMA identifies avatrombopag as a thrombopoietin receptor agonist and classifies it within the antihemorrhagic pharmacotherapeutic group.
Avatrombopag has established clinical uses in adults with certain platelet disorders. In the European Union, avatrombopag is indicated for severe thrombocytopenia associated with chronic liver disease in adults scheduled for an invasive procedure. It is also indicated for adults with primary chronic immune thrombocytopenia (ITP) who have not responded adequately to other treatments such as corticosteroids or immunoglobulins.
The treatment approach depends on why the platelet count is low, the patient's baseline platelet level, other medical conditions and the clinical situation.
For patients with chronic liver disease who need an invasive procedure, avatrombopag may be prescribed before the procedure to raise the platelet count and reduce the likelihood of needing platelet transfusion or rescue treatment. EMA reports that clinical studies demonstrated increased platelet levels and reduced need for platelet transfusion or rescue procedures in appropriate patients.
Avatrombopag is also used in chronic ITP when previous treatments have not provided an adequate response. In this setting, the goal is to increase platelet production and maintain a platelet level that helps reduce clinically important bleeding risk.
Avatrombopag Uses
1. Thrombocytopenia Associated With Chronic Liver Disease
Avatrombopag is used in adults with severe thrombocytopenia caused by chronic liver disease who are scheduled for an invasive procedure.
The medicine is intended to increase the platelet count before the procedure.
2. Primary Chronic Immune Thrombocytopenia
Avatrombopag is also indicated for adults with primary chronic ITP who have had an inadequate response to other treatments.
ITP is an immune-mediated condition in which platelet levels become abnormally low.
Patient-Friendly Explanation
Avatrombopag helps the body make more platelets. Doctors may prescribe it when a patient's platelet count is too low because of certain medical conditions.
Medical Explanation
Avatrombopag acts as a thrombopoietin receptor agonist, stimulating the thrombopoietin receptor pathway involved in megakaryocyte development and platelet production.
How Does Avatrombopag Work?
Avatrombopag works through the body's natural platelet-production system.
Normally, a hormone called thrombopoietin (TPO) binds to thrombopoietin receptors on cells involved in platelet production in the bone marrow. This signalling pathway promotes the development of megakaryocytes, the large bone-marrow cells that produce platelets.
Avatrombopag is designed to stimulate the same receptor pathway.
A simplified process can be represented as:
Avatrombopag → thrombopoietin receptor activation → megakaryocyte development → increased platelet production → higher platelet count
By activating the thrombopoietin receptor, avatrombopag supports proliferation and differentiation of megakaryocyte precursor cells. This ultimately increases the production of circulating platelets.
This mechanism is different from directly giving a patient a platelet transfusion. A transfusion supplies platelets from an external source, whereas avatrombopag stimulates the patient's own bone marrow to produce additional platelets.
For patients with chronic liver disease who have a planned invasive procedure, increasing the platelet count before the procedure can help reduce the need for platelet transfusion or other rescue treatment. EMA clinical data demonstrated this benefit in appropriately selected patients.
In chronic ITP, the immune system contributes to abnormally low platelet levels. Increasing platelet production through thrombopoietin receptor stimulation can help counterbalance platelet loss and support a safer platelet count.
The therapeutic response varies from patient to patient, so platelet counts must be assessed during treatment.
Key Indications
Chronic Liver Disease-Associated Thrombocytopenia
- Adult patients with severe thrombocytopenia
- Chronic liver disease-associated low platelet count
- Planned invasive medical procedure
- Treatment intended to increase platelet count before the procedure
Primary Chronic Immune Thrombocytopenia
- Adult patients with primary chronic ITP
- Patients who have not responded adequately to previous treatments
- May include patients previously treated with corticosteroids or immunoglobulins
Avapag 20 mg Dosage & Administration
The appropriate dosage of avatrombopag depends on the indication and the patient's platelet count.
For chronic liver disease-associated thrombocytopenia before an invasive procedure, treatment is generally started 10–13 days before the planned procedure. The dose depends on the patient's platelet count before treatment, and the procedure is scheduled 5–8 days after the final dose.
For chronic ITP, dosing is individualized according to platelet response and clinical requirements.
Important Administration Guidance
- Take avatrombopag exactly as prescribed.
- Take it at approximately the same time each day.
- Avatrombopag should be taken with food.
- Do not change the dose without medical advice.
- Platelet counts should be monitored according to the treatment plan.
- The medicine should be prescribed and monitored by an appropriately experienced healthcare professional.
Before an Invasive Procedure
For patients with chronic liver disease, platelet testing is required before treatment and again around the time of the procedure to confirm that the platelet response is appropriate.
Missed Dose
If a dose is missed, follow the instructions provided by the prescribing physician or pharmacist. Do not take additional tablets to compensate unless specifically instructed.
Avatrombopag Side Effects
As with other prescription medicines, avatrombopag can cause adverse effects.
Common Side Effects
Reported effects can include:
- Tiredness or fatigue
- Headache
- Nausea
- Abdominal discomfort
- Fever
- Respiratory symptoms in some patients
The EMA identifies fatigue as a common adverse effect of avatrombopag.
Less Common Side Effects
Depending on the clinical setting, patients may experience:
- Dizziness
- Gastrointestinal symptoms
- Musculoskeletal discomfort
- Changes associated with platelet response
Serious Side Effects
An important safety concern with medicines that increase platelet production is an excessively high platelet count and the potential for thrombotic or thromboembolic complications.
Patients should receive medical monitoring to maintain platelet levels within the clinically appropriate range.
When to Seek Medical Attention
Seek urgent medical attention if symptoms suggest a blood clot, such as:
- Sudden chest pain
- Difficulty breathing
- Sudden weakness
- Sudden speech or vision changes
- Severe or unusual headache
- Swelling or pain in one leg
Drug Interactions
Patients should inform their healthcare professional about all prescription medicines, over-the-counter products, vitamins and supplements.
Medicines Requiring Monitoring
Particular attention may be needed when avatrombopag is used with medicines that:
- Affect platelet function
- Increase bleeding risk
- Increase clotting risk
- Influence liver metabolism
- Are being used for other hematological conditions
Food Considerations
Avatrombopag should be taken with food, according to the product information.
Supplement Considerations
Tell the treating healthcare professional about:
- Herbal medicines
- Traditional medicines
- Vitamins
- Mineral supplements
- Blood-thinning supplements
- Unregulated products marketed for platelet or blood disorders
Warnings & Precautions
Thrombosis Risk
Because avatrombopag increases platelet production, excessive increases in platelet count may potentially contribute to thrombotic events.
Platelet monitoring is therefore important.
Chronic Liver Disease
Patients with liver disease may have complex changes in blood clotting and bleeding risk. Avatrombopag should be used according to the specific clinical indication and under appropriate medical supervision.
Cardiovascular Considerations
Patients with a history of:
- Blood clots
- Stroke
- Heart attack
- Deep-vein thrombosis
- Pulmonary embolism
should inform their physician before treatment.
Platelet Monitoring
The goal is not simply to produce the highest possible platelet count. The treatment objective is an appropriate platelet response for the patient's clinical situation.
For chronic liver disease patients undergoing an invasive procedure, platelet testing before treatment and on the procedure day is specifically recommended in the EMA product information.
Pregnancy & Breastfeeding
Pregnancy and breastfeeding decisions should be discussed with the treating healthcare professional before avatrombopag is started.
The potential benefits and risks should be assessed based on:
- The underlying platelet disorder
- Severity of thrombocytopenia
- Other available treatment options
- Pregnancy status
- Individual maternal and fetal considerations
Do not start or discontinue treatment during pregnancy or breastfeeding without medical advice.
Special Populations
Elderly Patients
Older adults may have additional medical conditions or take multiple medicines. Treatment should therefore be individualized with appropriate monitoring.
Pediatric Patients
Use in children depends on the specific indication, regulatory approval and specialist assessment. Avatrombopag should not be given to children without appropriate medical supervision.
Renal Impairment
Patients with kidney disease should inform their healthcare professional before starting treatment.
Hepatic Impairment
Many patients receiving avatrombopag have underlying liver disease. Treatment decisions should account for the severity and cause of hepatic disease and the specific indication for therapy.
Storage
Store Avapag according to the storage conditions printed on the product packaging.
General precautions:
- Keep the tablets in their original packaging.
- Protect the medicine from excessive heat and moisture.
- Keep out of reach of children.
- Do not use tablets that appear damaged.
- Do not use the medicine after its expiry date.
- Follow the labelled storage instructions supplied with the product.
Frequently Asked Questions
1. What is Avapag 20 mg used for?
Avapag 20 mg contains avatrombopag, a thrombopoietin receptor agonist used to increase platelet production in certain adults with thrombocytopenia. Approved uses include chronic liver disease-associated thrombocytopenia before an invasive procedure and primary chronic ITP in adults who have not responded adequately to previous treatments.
2. What is Avatrombopag?
Avatrombopag is an oral thrombopoietin receptor agonist that stimulates the body's platelet-production pathway.
3. How does Avatrombopag increase platelets?
It activates the thrombopoietin receptor pathway, supporting megakaryocyte development and increasing platelet production in the bone marrow.
4. Is Avatrombopag used for low platelets?
Yes. Avatrombopag is specifically used for certain forms of thrombocytopenia.
5. Can Avatrombopag be used before surgery?
It can be used before certain invasive procedures in adults with severe thrombocytopenia associated with chronic liver disease. Treatment is started before the planned procedure according to the prescribed schedule.
6. Is Avatrombopag used for ITP?
Yes. In the EU, avatrombopag is indicated for primary chronic ITP in adults who are refractory to other treatments.
7. Should Avatrombopag be taken with food?
Yes. The EMA product information states that avatrombopag should be taken with food.
8. What are common Avatrombopag side effects?
Fatigue is identified by the EMA as a common adverse effect. Other effects depend on the patient's condition and treatment setting.
9. Does Avatrombopag require platelet monitoring?
Yes. Monitoring platelet counts is important to assess the response and avoid an unexpectedly high platelet count.
10. Can Avatrombopag cause blood clots?
Medicines that increase platelet production can be associated with thrombotic risk, particularly when platelet counts become excessively high. Patients with clotting risk factors should be carefully assessed.
11. How long before a procedure is Avatrombopag started?
For chronic liver disease-associated thrombocytopenia, treatment should begin approximately 10–13 days before the planned invasive procedure under the approved regimen.
12. Is Avatrombopag a platelet transfusion?
No. Avatrombopag does not directly supply platelets. It stimulates the body's platelet-production pathway.
13. What class of medicine is Avatrombopag?
Avatrombopag is a thrombopoietin receptor agonist and is classified pharmacotherapeutically as an antihemorrhagic medicine.
14. Can Avatrombopag be used during pregnancy?
Pregnancy-related use should be decided by a qualified healthcare professional after an individual benefit-risk assessment.
15. Is Avapag 20 mg a prescription medicine?
Avatrombopag is a prescription medicine and should be used under appropriate medical supervision.
Global Medicine Information & Support by RootAid Pharma
Global Medicine Information & Support by RootAid Pharma
RootAid Pharma provides educational medicine information and international support relating to prescription and specialty medicines.
Our medicine-information resources cover areas including:
- Hematology medicines
- Platelet disorders
- Thrombocytopenia treatment
- Immune thrombocytopenia
- Oncology medicines
- Prescription medicine information
- Specialty medicine support
- International medicine information
For medicines such as avatrombopag, treatment decisions should remain under the supervision of a qualified healthcare professional.
RootAid Pharma provides medicine-related information and supply assistance where legally applicable. Availability, prescription requirements, import rules and regulatory requirements can differ between countries.
RootAid Pharma does not claim to manufacture Avapag or avatrombopag.
Need help after reading this?
Talk to our support team for sourcing guidance, product availability, and global delivery assistance.